Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL

NCT03407859 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT03407859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03407859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
Lead sponsor
Zhujiang Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
January 18, 2016
Completion date
March 31, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

therapy related leukemia